Experience with topical brimonidine (Alphagan® 0,2%) in the treatment of glaucomas;Traitement des glaucomes par la brimonidine (Alphagan® 0,2 %)

Journal Francais d'Ophtalmologie

Volumn 23, Issue 8, 2000, Pages 763-768

  Detry Morel, M ^a   Dutrieux, C ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Brimonidine; Glaucoma

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CONJUNCTIVITIS; DROWSINESS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; FATIGUE; FEMALE; GLAUCOMA; HIGH RISK PATIENT; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; XEROSTOMIA;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; CHILD; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA; HUMANS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; QUINOXALINES;

EID: 0033794537     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Preclinical evaluation of brimonidine
2. Changing therapeutic paradigms in glaucoma management
3. Brimonidine Tartrate. A one-month dose response study
4. An in-service investigation of the additive effect of topical adrenergic agonists and beta-blockers
5. Brimonidine: A new alpha-adrenoreceptor agonist for glaucoma treatment
6. Twelve-month results of an ongoing randomized trial comparing Brimonidine Tartrate 0.2% and Timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension
7. A comparison of the safety and efficacy of twice daily Brimonidine 0.2% versus Betaxolol 0.25% in subjects with elevated Intraocular pressure
8. Development and use of brimonidine in treating acute and chronic elevation of intraocular pressure: A review of safety, efficacy, dose response, and dosing studies
9. The role of Brimonidine in the treatment of open-angle glaucoma
10. The short-term effect of adding Brimonidine 0.2% to Timolol treatment in patients with open-angle glaucoma
11. From the lab to the clinic: Activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury
12. alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration
13. Brimonidine Tartrate 02% twice daily vs timolol 05% twice daily 1-year results in glaucoma patients
14. Clinical Experience with Brimonidine 0.2% and Timolol 0.5% in Glaucoma and Ocular Hypertension
15. Efficacy of Brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequatly controlled with otherwise maximal medical therapy
16. Apparent Central Nervous System Depression in Infants after the use of topical brimonidine
17. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy
18. Long-term Brimonidine therapy in Glaucoma patients with Apraclonidine Allergy
19. Mechanisms of Adrenergic Agonist Induced Allergy Bioactivation and Antigen Formation